## Biosimilars

are biological medicinal products that are very similar to an already authorised biological medicinal product.

## Biosimilars are interchangeable

They can be used instead of their reference medicinal product or another biosimilar of the same reference product.



86

Biosimilars have been authorised in the EU since 2006. (Status September 2022)

Therapy areas are for example:



Cancer



neurological diseases



Paul-Ehrlich-Institut

Rheumatoid arthritis